Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진기 | - |
dc.date.accessioned | 2018-06-19T07:34:22Z | - |
dc.date.available | 2018-06-19T07:34:22Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.citation | JOURNAL OF MICROENCAPSULATION, v. 34, No. 3, Page. 250-261 | en_US |
dc.identifier.issn | 0265-2048 | - |
dc.identifier.issn | 1464-5246 | - |
dc.identifier.uri | https://www.tandfonline.com/doi/abs/10.1080/02652048.2017.1337247 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/72162 | - |
dc.description.abstract | The aim of this study was to develop docetaxel-incorporated lipid nanoparticles (DTX-NPs) to improve the pharmacokinetic behaviour of docetaxel (DTX) after oral and parenteral administration via sustained release. DTX-NPs were prepared by nanotemplate engineering technique with palmityl alcohol as a solid lipid and Tween-40/Span-40/Myrj S40 as a surfactants mixture. Spherical DTX-NPs below 100 nm were successfully prepared with a narrow particle size distribution, 96% of incorporation efficiency and 686 times increase in DTX solubility. DTX-NPs showed a sustained release over 24 h in phosphate-buffered saline and simulated gastric and intestinal fluids, while DTX-micelles released DTX completely within 12 h. The half-maximal inhibitory concentration (IC50) of DTX-NPs against human breast cancer MCF-7 cells was 1.9 times lower than that of DTX-micelles and DTX solution. DTX-NPs demonstrated 3.7- and 2.8-fold increase in the area under the plasma concentration-time curve compared with DTX-micelles after oral and parenteral administration, respectively. | en_US |
dc.description.sponsorship | This work was supported by the research fund of Hanyang University (HY-2012-N). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | TAYLOR & FRANCIS LTD | en_US |
dc.subject | Lipid nanoparticles | en_US |
dc.subject | docetaxel | en_US |
dc.subject | sustained release | en_US |
dc.subject | pharmacokinetics | en_US |
dc.subject | bioavailability | en_US |
dc.subject | CONTROLLED DRUG-DELIVERY | en_US |
dc.subject | IN-VIVO EVALUATION | en_US |
dc.subject | ANTICANCER DRUGS | en_US |
dc.subject | TUMOR MICROENVIRONMENT | en_US |
dc.subject | VITRO | en_US |
dc.subject | CYTOTOXICITY | en_US |
dc.subject | NANOCARRIERS | en_US |
dc.subject | CARRIERS | en_US |
dc.subject | SYSTEMS | en_US |
dc.subject | SLN | en_US |
dc.title | Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 34 | - |
dc.identifier.doi | 10.1080/02652048.2017.1337247 | - |
dc.relation.page | 250-261 | - |
dc.relation.journal | JOURNAL OF MICROENCAPSULATION | - |
dc.contributor.googleauthor | Qureshi, Omer Salman | - |
dc.contributor.googleauthor | Kim, Hyung-Seo | - |
dc.contributor.googleauthor | Zeb, Alam | - |
dc.contributor.googleauthor | Choi, Jin-Seok | - |
dc.contributor.googleauthor | Kim, Hoo-Seong | - |
dc.contributor.googleauthor | Kwon, Jung-Eun | - |
dc.contributor.googleauthor | Kim, Myung-Sic | - |
dc.contributor.googleauthor | Kang, Jong-Ho | - |
dc.contributor.googleauthor | Ryou, Chongsuk | - |
dc.contributor.googleauthor | Kim, Jin-Ki | - |
dc.contributor.googleauthor | Park, Jeong-Sook | - |
dc.relation.code | 2017001623 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | jinkikim | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.